Welcome To DiagnOmix
Early Detection. Personalized Prevention. Lifelong Health.
DiagnOmix fuses omnics big data, systems biology, AI, biomarker and drug discovery to transform women’s healthcare from prenatal health to chronic deseases prevention, paving the way for a healthier, longer, disease-free life.
Market Opportunity
Millions of women worldwide face preventable health risks each year related to pregnancy, leading to multigenerational health consequences that also affect their families. Cardiometabolic, endocrine, and metabolic complications contribute to women’s long-term health burden, including heart disease, diabetes, and stroke, and may impact the next generation through preterm birth, low birth weight, fetal programming, and developmental disorders. Globally, healthcare systems spend tens of billions annually on acute care, yet most interventions address symptoms rather than underlying causes or long-term prevention.
DiagnOmix introduces a paradigm shift. Our biomarker-based, AI-driven diagnostic platform enables early disease detection and personalised health prevention across the female lifespan — from birth through fertility and pregnancy to healthy aging. By identifying risks months or years before complications emerge, we can help protect millions of women and their families, support long-term wellness, improve lifelong outcomes, and reduce healthcare costs.
Impact Statement (bold takeaway):
“DiagnOmix empowers women worldwide with early detection and personalized care, supporting wellness and preventing chronic disease; therefore, transforming long-term health outcomes for generations.”
Our Company
DiagnOmix is a medtech start-up specializing in omics-driven diagnostics, AI-based risk prediction, and digital twin technologies.
Our mission: empower individuals and healthcare systems to move from reactive treatment toward proactive, preventive, and personalized medicine.
Our Vision
We are creating a paradigm shift in diagnostics, moving healthcare from reactive to preventive, predictive, and pre-emptive.
By combining machine learning, systems biology, and precision medicine, DiagnOmix contributes to building a truly 21st century healthcare system.
We envision a future where:
-
-
-
- Diseases are detected before symptoms appear
- Preventive therapies extend the number of healthy life years
- Generational disease burdens (cardiometabolic, maternal, neurodegenerative) are reduced through data-driven insights
- Everyone has access to a digital health twin that guides prevention and personalized care
-
-
Team
In progress…
Collaborator Partners
Our Solution
DiagnOmix integrates omics big data, AI algorithms, and systems biology into unified diagnostic workflows.
By combining digital twin integration with liquid biopsy biomarker discovery, we deliver precision screening and patient-specific prevention roadmaps.
Our diagnostic test and risk-assessment software provide accurate, early detection of wide range of deseases, supporting proactive and personalized healthcare.
Benefits extend beyond individual patients – contributing to healthier families, reduced healthcare costs, and longer, disease-free lives for society as a whole.
Benefits:
For patients
Early diagnosis & personalized therapies
For governments
Lower healthcare expenditures
For insurance providers
Reduced rick & costs
For investors
Access to the fast-growing FemTech & precision diagnostics markets
For society
Saving lives, improving long-therm health outcomes
Research & Funding
Ongoing translational research across Europe, Israel, and the US.
Multiple active EU and Hungarian grants supporting biomarker validation and prototype development.
Headquarters
EU: Biatorbágy, Hungary